Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: December 2, 2010
Last updated: May 5, 2011
Last verified: May 2011
This is a study in healthy adult volunteers to assess the bioequivalence of over-encapsulated oseltamivir capsules to commercially available oseltamivir capsules. Both formulations will be administered in the fasting state.

Condition Intervention Phase
Influenza, Human
Drug: over-encapsulated oseltamivir
Drug: oseltamivir
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Plasma oseltamivir carboxylate area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir carboxylate maximum observed concentration (Cmax) [ Time Frame: 9 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Plasma oseltamivir carboxylate area under the concentration-time curve from time zero (pre-dose) to the time of the last quantifiable concentration (AUC(0-t)) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir carboxylate terminal phase half-life (t1/2) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir carboxylate time of occurrence of Cmax (tmax) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir AUC (0-infinity) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir AUC(0-t) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir Cmax [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir t1/2 [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir lag time before observation of drug concentrations in sampled matrix (tlag) [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Plasma oseltamivir tmax [ Time Frame: 9 days ] [ Designated as safety issue: No ]
  • Safety and tolerability of all treatments, including number of subjects with adverse events assessment [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Safety and tolerability of all treatments, including number of subjects with concurrent medications [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Safety and tolerability of all treatments, change from baseline and number subjects with abnormal clinical safety laboratory data [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Safety and tolerability of all treatments, including change from baseline and number of subjects with abnormal ECG assessments [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Safety and tolerability of all treatments, including change from baseline and number of subjects with abnormal vital signs (blood pressure and heart rate) assessments [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Plasma oseltamivir carboxylate lag time before observation of drug concentrations in sampled matrix(tlag) [ Time Frame: 9 days ] [ Designated as safety issue: No ]

Enrollment: 28
Study Start Date: December 2010
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment A
Over-encapsulated oseltamivir 75 mg (1 capsule)
Drug: over-encapsulated oseltamivir
75 mg once
Experimental: Treatment B
oseltamivir 75 mg (1 capsule)
Drug: oseltamivir
75 mg once


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • AST, ALT, alkaline phosphatase and bilirubin greater than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of: Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit.
  • Body weight greater than or equal to 50 kg and BMI within the range 18.5 - 31.0 kg/m2 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • A positive test for HIV antibody.
  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy, peptic ulceration, inflammatory bowel disease or pancreatitis should be excluded.
  • The subject's systolic blood pressure is outside the range of 90-140 mmHg, or diastolic blood pressure is outside the range of 45-90 mmHg or heart rate is outside the range of 50-100 bpm for female subjects or 45-100 bpm for male subjects.
  • Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate Males <45 and >100 bpm Females <50 and >100 bpm; PR Interval <120 and >220 msec; QRS duration <70 and >120 msec; QTc interval (Bazett) >450 msec.

Evidence of previous myocardial infarction (Does not include ST segment changes associated with repolarization).

Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome, non-sustained or sustained ventricular tachycardia (greater than or equal to 3 consecutive ventricular ectopic beats).sinus pauses > 3 seconds, or other significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01258530

United States, New York
GSK Investigational Site
Buffalo, New York, United States, 14202
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT01258530     History of Changes
Other Study ID Numbers: 115096 
Study First Received: December 2, 2010
Last Updated: May 5, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
influenza, bioequivalence, oseltamivir, Tamiflu, over-encapsulation

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on October 26, 2016